Comparative Pharmacology
Head-to-head clinical analysis: COLYTE WITH FLAVOR PACKS versus PORTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLYTE WITH FLAVOR PACKS versus PORTALAC.
COLYTE WITH FLAVOR PACKS vs PORTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., acetic, lactic, and formic acid), resulting in acidification of colonic contents and an increase in osmotic pressure, which stimulates bowel evacuation. In hepatic encephalopathy, acidification reduces blood ammonia levels by converting NH3 to NH4+ in the colon, inhibiting ammonia absorption.
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 mL every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
Initial: 15-30 mL (10-20 g lactulose) orally, 2-3 times daily; titrate to 2-3 soft stools daily. For acute hepatic encephalopathy: 30-45 mL (20-30 g) orally every hour until evacuation, then 3-4 times daily.
None Documented
None Documented
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
1.7-2.0 hours (terminal); clinical context: short t1/2 allows rapid dose adjustment in hepatic encephalopathy.
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
Renal: ~40% as unchanged drug; fecal: ~60% as metabolites (biliary excretion of conjugates and lactulose).
Category C
Category C
Osmotic Laxative
Osmotic Laxative